DD218619A5 - Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten - Google Patents

Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten Download PDF

Info

Publication number: DD218619A5
Authority: DD; German Democratic Republic
Prior art keywords: compounds; general formula; chloro; cis; methyl
Prior art date: 1983-06-03

Application number

DD84263713A

Other languages

German (de)

English (en)

Inventor

Mikio Takeda

Tokuro Oh-Ishi

Hiromichi Nakajima

Taku Nagao

Original Assignee

Tanabe Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-03

Filing date

1984-06-01

Publication date

1985-02-13

1983-06-03 Priority claimed from GB838315364A external-priority patent/GB8315364D0/en

1984-01-14 Priority claimed from GB848400983A external-priority patent/GB8400983D0/en

1984-06-01 Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co

1985-02-13 Publication of DD218619A5 publication Critical patent/DD218619A5/de

Links

JQNJUZUDWVHVHJ-UHFFFAOYSA-N 8-chloro-1,5-benzothiazepine Chemical class N1=CC=CSC2=CC(Cl)=CC=C21 JQNJUZUDWVHVHJ-UHFFFAOYSA-N 0.000 title claims abstract description 5
238000000034 method Methods 0.000 title claims description 45
238000002360 preparation method Methods 0.000 title claims description 20
150000003839 salts Chemical class 0.000 claims abstract description 69
239000002253 acid Substances 0.000 claims abstract description 43
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 34
125000000217 alkyl group Chemical group 0.000 claims abstract description 9
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
150000001875 compounds Chemical class 0.000 claims description 151
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 57
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 19
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 12
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 11
125000004432 carbon atom Chemical group C* 0.000 claims description 10
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 5
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 4
SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical group COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 claims 1
101100468652 Drosophila melanogaster rho-5 gene Proteins 0.000 claims 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
230000002490 cerebral effect Effects 0.000 abstract description 15
229940124549 vasodilator Drugs 0.000 abstract description 4
239000003071 vasodilator agent Substances 0.000 abstract description 4
239000002220 antihypertensive agent Substances 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 139
239000000203 mixture Substances 0.000 description 83
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 79
-1 2- (dimethylamino) ethyl Chemical group 0.000 description 67
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 61
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 56
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 51
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 46
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 39
239000002904 solvent Substances 0.000 description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 30
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 29
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 25
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 25
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
239000000047 product Substances 0.000 description 24
239000013078 crystal Substances 0.000 description 19
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 18
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
230000000694 effects Effects 0.000 description 15
229910000027 potassium carbonate Inorganic materials 0.000 description 13
239000003795 chemical substances by application Substances 0.000 description 12
OTGHWLKHGCENJV-UHFFFAOYSA-N glycidic acid Chemical compound OC(=O)C1CO1 OTGHWLKHGCENJV-UHFFFAOYSA-N 0.000 description 12
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
239000012043 crude product Substances 0.000 description 9
235000019260 propionic acid Nutrition 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000017531 blood circulation Effects 0.000 description 8
238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
238000002844 melting Methods 0.000 description 8
230000008018 melting Effects 0.000 description 8
239000012452 mother liquor Substances 0.000 description 8
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 8
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
230000001077 hypotensive effect Effects 0.000 description 7
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
230000003287 optical effect Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
238000001816 cooling Methods 0.000 description 6
229910052751 metal Inorganic materials 0.000 description 6
239000002184 metal Substances 0.000 description 6
239000002244 precipitate Substances 0.000 description 6
208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
239000007858 starting material Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
239000008096 xylene Substances 0.000 description 6
FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 5
150000008065 acid anhydrides Chemical class 0.000 description 5
239000002585 base Substances 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
229960001789 papaverine Drugs 0.000 description 5
238000010956 selective crystallization Methods 0.000 description 5
238000011699 spontaneously hypertensive rat Methods 0.000 description 5
230000000304 vasodilatating effect Effects 0.000 description 5
210000002385 vertebral artery Anatomy 0.000 description 5
LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
208000001953 Hypotension Diseases 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000000370 acceptor Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
150000007657 benzothiazepines Chemical class 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
210000004351 coronary vessel Anatomy 0.000 description 4
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
208000021822 hypotensive Diseases 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
229910000029 sodium carbonate Inorganic materials 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 3
WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylamino-1-chloro-ethane hydrochloride Natural products CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 3
RQEQBGNHQNCKCS-UHFFFAOYSA-N 5-chloro-2-nitrobenzenethiol Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1S RQEQBGNHQNCKCS-UHFFFAOYSA-N 0.000 description 3
229930008281 A03AD01 - Papaverine Natural products 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
239000012346 acetyl chloride Substances 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000003218 coronary vasodilator agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
150000003840 hydrochlorides Chemical class 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
235000011150 stannous chloride Nutrition 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
XSZLQXJZTUQQII-HOCLYGCPSA-N (2S,3S)-8-chloro-2-(4-methoxyphenyl)-2,3-dihydro-1,5-benzothiazepin-3-ol Chemical compound COC1=CC=C(C=C1)[C@@H]1SC2=C(N=C[C@@H]1O)C=CC(=C2)Cl XSZLQXJZTUQQII-HOCLYGCPSA-N 0.000 description 2
KAANMZCKNKVSAA-CABCVRRESA-N (2s,3s)-8-chloro-3-hydroxy-2-(4-methoxyphenyl)-3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](O)C(=O)NC2=CC=C(Cl)C=C2S1 KAANMZCKNKVSAA-CABCVRRESA-N 0.000 description 2
DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
TYRZAGMAVZESQX-UHFFFAOYSA-N 2-amino-5-chlorobenzenethiol Chemical compound NC1=CC=C(Cl)C=C1S TYRZAGMAVZESQX-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
PPQXADXGECUTFI-UHFFFAOYSA-N 5h-1,5-benzothiazepin-4-one Chemical compound S1C=CC(=O)NC2=CC=CC=C21 PPQXADXGECUTFI-UHFFFAOYSA-N 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
208000018152 Cerebral disease Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
229960001138 acetylsalicylic acid Drugs 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
206010003119 arrhythmia Diseases 0.000 description 2
230000006793 arrhythmia Effects 0.000 description 2
229940085242 benzothiazepine derivative selective calcium channel blockers with direct cardiac effects Drugs 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 2
229960001412 pentobarbital Drugs 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000006340 racemization Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000001119 stannous chloride Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000011135 tin Substances 0.000 description 2
229910052718 tin Inorganic materials 0.000 description 2
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
238000005303 weighing Methods 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
HSQFVBWFPBKHEB-UHFFFAOYSA-N 2,3,4-trichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1Cl HSQFVBWFPBKHEB-UHFFFAOYSA-N 0.000 description 1
PWOBDMNCYMQTCE-UHFFFAOYSA-N 2-chlorobenzenethiol Chemical compound SC1=CC=CC=C1Cl PWOBDMNCYMQTCE-UHFFFAOYSA-N 0.000 description 1
RAGSWDIQBBZLLL-UHFFFAOYSA-N 2-chloroethyl(diethyl)azanium;chloride Chemical compound Cl.CCN(CC)CCCl RAGSWDIQBBZLLL-UHFFFAOYSA-N 0.000 description 1
CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
VNUDPFLTWOKTKQ-UHFFFAOYSA-N 3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound N1C(=O)CCSC2=CC=CC=C21 VNUDPFLTWOKTKQ-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
LKAOPBFMTSRRQE-UHFFFAOYSA-N 5H-1,5-benzothiazepin-4-one hydrochloride Chemical compound Cl.S1C=CC(=O)NC2=CC=CC=C21 LKAOPBFMTSRRQE-UHFFFAOYSA-N 0.000 description 1
DCFYOFYHECMATR-UHFFFAOYSA-N 5h-1,2-benzothiazepin-4-one;hydrochloride Chemical compound Cl.S1N=CC(=O)CC2=CC=CC=C21 DCFYOFYHECMATR-UHFFFAOYSA-N 0.000 description 1
VPDZTCQGTVGJNX-UHFFFAOYSA-N 5h-thiazepin-4-one;hydrochloride Chemical compound Cl.O=C1CC=CSN=C1 VPDZTCQGTVGJNX-UHFFFAOYSA-N 0.000 description 1
UINRCHSSGCCNDO-UHFFFAOYSA-N 7-chloro-1,5-benzothiazepine Chemical class S1C=CC=NC2=CC(Cl)=CC=C21 UINRCHSSGCCNDO-UHFFFAOYSA-N 0.000 description 1
LQZWSQAUCXSOFL-UHFFFAOYSA-N 8-chloro-2-hydroxy-3,5-dihydro-2H-1,5-benzothiazepin-4-one Chemical compound OC1SC2=C(NC(C1)=O)C=CC(=C2)Cl LQZWSQAUCXSOFL-UHFFFAOYSA-N 0.000 description 1
WYWKPNIAGOEYTD-UHFFFAOYSA-N 8-chloro-3,5-dihydro-2h-1,5-benzothiazepin-4-one Chemical compound N1C(=O)CCSC2=CC(Cl)=CC=C21 WYWKPNIAGOEYTD-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229910015900 BF3 Inorganic materials 0.000 description 1
ZLMUQXJBNKPTJU-UHFFFAOYSA-N Cl.ClC1=CC2=C(NC(CCS2)=O)C=C1 Chemical compound Cl.ClC1=CC2=C(NC(CCS2)=O)C=C1 ZLMUQXJBNKPTJU-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
239000012891 Ringer solution Substances 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
IKJIITMEIPMVQE-SJORKVTESA-N [(2s,3s)-8-chloro-2-(4-methoxyphenyl)-4-oxo-3,5-dihydro-2h-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)NC2=CC=C(Cl)C=C2S1 IKJIITMEIPMVQE-SJORKVTESA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000008051 alkyl sulfates Chemical class 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical class C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 1
KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Chemical class C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
229960003750 ethyl chloride Drugs 0.000 description 1
WMYNMYVRWWCRPS-UHFFFAOYSA-N ethynoxyethane Chemical group CCOC#C WMYNMYVRWWCRPS-UHFFFAOYSA-N 0.000 description 1
239000011790 ferrous sulphate Substances 0.000 description 1
235000003891 ferrous sulphate Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
229960005337 lysine hydrochloride Drugs 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
SYPJDLNUUCJWMV-UHFFFAOYSA-N methanol;propanoic acid Chemical compound OC.CCC(O)=O SYPJDLNUUCJWMV-UHFFFAOYSA-N 0.000 description 1
UYCKVJUNDXPDJH-DDWIOCJRSA-N methyl (2r)-2-amino-2-(4-hydroxyphenyl)acetate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)C1=CC=C(O)C=C1 UYCKVJUNDXPDJH-DDWIOCJRSA-N 0.000 description 1
UYCKVJUNDXPDJH-QRPNPIFTSA-N methyl (2s)-2-amino-2-(4-hydroxyphenyl)acetate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)C1=CC=C(O)C=C1 UYCKVJUNDXPDJH-QRPNPIFTSA-N 0.000 description 1
DKLZRLRMFNWRFB-UHFFFAOYSA-N methyl 2-(4-hydroxyanilino)acetate Chemical compound COC(=O)CNC1=CC=C(O)C=C1 DKLZRLRMFNWRFB-UHFFFAOYSA-N 0.000 description 1
BHFLUDRTVIDDOR-UHFFFAOYSA-N methyl 2-amino-2-phenylacetate Chemical class COC(=O)C(N)C1=CC=CC=C1 BHFLUDRTVIDDOR-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
CYCFYXLDTSNTGP-UHFFFAOYSA-L octadecanoate;tin(2+) Chemical compound [Sn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CYCFYXLDTSNTGP-UHFFFAOYSA-L 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
238000005496 tempering Methods 0.000 description 1
230000002446 thrombocytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
229940125725 tranquilizer Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
YZYKBQUWMPUVEN-UHFFFAOYSA-N zafuleptine Chemical compound OC(=O)CCCCCC(C(C)C)NCC1=CC=C(F)C=C1 YZYKBQUWMPUVEN-UHFFFAOYSA-N 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
239000004246 zinc acetate Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J123/00—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers
- C09J123/02—Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers not modified by chemical after-treatment
- C09J123/04—Homopolymers or copolymers of ethene
- C09J123/08—Copolymers of ethene
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

DD84263713A 1983-06-03 1984-06-01 Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten DD218619A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB838315364A GB8315364D0 (en)	1983-06-03	1983-06-03	8-chloro-1 5-benzothiazepine derivatives
GB848400983A GB8400983D0 (en)	1984-01-14	1984-01-14	8-chloro-1,5-benzothiazepine derivatives

Publications (1)

Publication Number	Publication Date
DD218619A5 true DD218619A5 (de)	1985-02-13

Family

ID=26286299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD84263713A DD218619A5 (de)	1983-06-03	1984-06-01	Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten

Country Status (18)

Country	Link
US (1)	US4567175A (da)
EP (1)	EP0127882B1 (da)
KR (1)	KR900005697B1 (da)
AT (1)	ATE22889T1 (da)
AU (1)	AU563093B2 (da)
BG (2)	BG40964A3 (da)
CA (2)	CA1237719A (da)
DD (1)	DD218619A5 (da)
DE (1)	DE3460972D1 (da)
DK (2)	DK167185B1 (da)
ES (2)	ES8506677A1 (da)
HK (1)	HK81888A (da)
HU (2)	HU193865B (da)
MY (1)	MY101748A (da)
NO (2)	NO162518C (da)
PH (1)	PH21627A (da)
PT (1)	PT78682B (da)
SU (2)	SU1299508A3 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4585768A (en) *	1984-04-10	1986-04-29	Tanabe Seiyaku Co., Ltd.	1,5-benzothiazepine derivatives and processes for preparing the same
GB2167063A (en) *	1984-11-17	1986-05-21	Tanabe Seiyaku Co	6 or 9-chloro-1, 5-benzothiazepine derivatives
USRE33072E (en) *	1985-06-20	1989-09-26	E. R. Squibb & Sons, Inc.	Benzothiazepine derivatives
US4584131A (en) *	1985-06-20	1986-04-22	E. R. Squibb & Sons, Inc.	Benzothiazepine derivatives
JPS62161776A (ja) *	1986-01-07	1987-07-17	Tanabe Seiyaku Co Ltd	１，５−ベンゾチアゼピン誘導体の製法
US4652561A (en) *	1986-02-26	1987-03-24	Hoffmann-La Roche Inc.	Naphtho[1,2-b]-1,4-thiazepinones
IL81954A0 (en) *	1986-03-24	1987-10-20	Hoffmann La Roche	Naphthothiazocinones,their manufacture and pharmaceutical compositions containing them
US4778791A (en) *	1986-05-16	1988-10-18	Tanabe Seiyaku Co., Ltd.	Pharmaceutical composition for improving constitution of lipids in blood
US4786634A (en) *	1986-05-23	1988-11-22	Tanabe Seikyaku Co., Ltd.	Method for treating arteriosclerosis
ATE64925T1 (de) *	1986-08-20	1991-07-15	Mcneilab Inc	Benzothiazepin-vasodilatoren mit aralkylsubstitution.
IL85257A (en) *	1987-02-10	1993-02-21	Tanabe Seiyaku Co	Pharmaceutical compositions containing 2-(4-methoxyphenyl) 3-acetoxy-5-- (2-(dimethylamino) ethyl) -8-chloro-2,3- dihydro-1,5-benzothiazepin -4 (5h)-one having renal function-improving effect and diuretic effect
JPS6450872A (en) *	1987-08-21	1989-02-27	Tanabe Seiyaku Co	Production of 1,5-benzothiazepine derivative
JPS6445376A (en) *	1987-08-12	1989-02-17	Tanabe Seiyaku Co	Production of 1,5-benzothiazepine derivative
AT389446B (de) *	1987-10-08	1989-12-11	Tanabe Seiyaku Co	Verwendung eines 8-chlorobenzothiazepins zur herstellung eines arzneimittels
US4808580A (en) *	1987-12-17	1989-02-28	Hoffmann-La Roche Inc.	Naphtho[1,2-b][1,4]thiazepin-4(5H)-ones and use thereof in treatment of ischemia and blood pressure lowering
US4908469A (en) *	1988-05-18	1990-03-13	Marion Laboratories, Inc.	2-Hydroxy-propanoic acid acyclic alkyl esters for benzothiazepines
US4879289A (en) *	1988-05-24	1989-11-07	Marion Laboratories, Inc.	Method of ameliorating epileptic seizures
US4963545A (en) *	1988-05-24	1990-10-16	Marion Laboratories, Inc.	Benzothiazepine anti-seizure method
US4902684A (en) *	1988-06-20	1990-02-20	E. R. Squibb & Sons, Inc.	Benzazepine and benzothiazepine derivatives
US5002942A (en) *	1988-07-25	1991-03-26	Sankyo Company, Limited	1,5-benzothiazepine derivatives, their preparation and their use in the treatment of cardiovascular disorders
IT1226301B (it) *	1988-07-26	1990-12-27	Zambon Spa	Processo per la preparazione di intermedi per la sintesi del diltiazem.
FR2637285B1 (fr) *	1988-10-03	1991-04-12	Synthelabo	Procede de preparation de derives de l'acide propionique et produits obtenus
US4952692A (en) *	1989-04-04	1990-08-28	E. R. Squibb & Sons, Inc.	Benzazepine derivatives
US4946840A (en) *	1989-04-06	1990-08-07	E. R. Squibb & Sons, Inc.	Benzazepine and benzothiazepine derivatives
IT1230057B (it) *	1989-04-13	1991-09-27	Zambon Spa	Processo di risoluzione di intermedi utili per la preparazione di 1,5-benzotiazepine
US5128469A (en) *	1989-04-28	1992-07-07	Tanabe Seiyaku Co., Ltd.	Process for preparing 1,5-benzothiazepine derivatives
ATE116643T1 (de) *	1989-04-28	1995-01-15	Tanabe Seiyaku Co	Verfahren zur herstellung von 1,5- benzothiazepinderivaten.
US5250680A (en) *	1989-08-31	1993-10-05	Merrell Dow Pharmaceuticals Inc.	Heterogeneous synthesis of azepinones from esters
ZA906810B (en) *	1989-08-31	1991-10-30	Marion Merrell Dow Inc	Heterogeneous synthesis of azepinones from esters
US5244803A (en) *	1989-09-13	1993-09-14	Tanabe Seiyaku Co., Ltd.	Process for preparing optically active 3-phenylglycidic acid esters
CA2030159A1 (en) *	1989-11-22	1991-05-23	Nahed K. Ahmed	Anti-cancer drug potentiators
US5001236A (en) *	1989-11-22	1991-03-19	Marion Laboratories, Inc.	Benzothiazepines
CA2030160A1 (en) *	1989-11-22	1991-05-23	Nahed K. Ahmed	Benzothiazepine metastasis treatment
US5112969A (en) *	1990-04-02	1992-05-12	Merrell Dow Pharmaceuticals Inc.	Cyano esters and azepinones
US5055575A (en) *	1990-04-12	1991-10-08	Tanabe Seiyaku Co., Ltd.	Process for preparing 1,5-benzothiazepine derivatives
IT1240651B (it) *	1990-05-17	1993-12-17	Zambon Spa	Processo per la risoluzione di derivati glicidici
CA2049655C (en) *	1990-09-17	1996-11-12	Akio Odawara	Pharmaceutical composition for inhibiting platelet aggregation
WO1992020326A1 (en) *	1991-05-20	1992-11-26	Marion Laboratories, Inc.	Multi-layered controlled release formulation
US5378698A (en) *	1991-10-21	1995-01-03	Shionogi & Co., Ltd.	Benzothiazepine derivatives
CA2087743C (en) *	1992-02-06	1999-04-27	Akio Odawara	Pharmaceutical composition for inhibiting platelet aggregation
KR950003279A (ko) *	1993-07-29	1995-02-16	고사이 아끼오	플루오로알칸 카르복사미드 유도체의 제조방법
US5705638A (en) *	1995-12-05	1998-01-06	Tanabe Seiyaku Co., Ltd.	Process for preparing optically active 3-hydroxy-1,5-benzothiazepine derivative and intermediate therefor
DE69601210T2 (de) *	1995-12-05	1999-05-20	Tanabe Seiyaku Co., Ltd., Osaka	Optisch aktive Benzothiazepinderivate und Verfahren zu ihrer Herstellung
SG50796A1 (en) *	1996-02-23	1998-07-20	Tanabe Seiyaku Co	Process for preparing 1,5-benzothiazepine derivative
IT1302261B1 (it)	1998-09-24	2000-09-05	Zambon Spa	Processo per la risoluzione cinetica enzimatica di 3-fenilglicidatiper transesterificazione con amminoalcoli
AU2003250483A1 (en)	2002-08-19	2004-03-11	Pfizer Products Inc.	Combination therapy for hyperproliferative diseases
US20050037063A1 (en) *	2003-07-21	2005-02-17	Bolton Anthony E.	Combined therapies
JP2008507585A (ja) *	2004-07-26	2008-03-13	コセリックスインク	微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
AP2007003979A0 (en) *	2004-11-23	2007-06-30	Warner Lambert Co	7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
WO2007050783A2 (en) *	2005-10-26	2007-05-03	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP2351569B1 (en)	2005-10-26	2012-08-22	Asahi Kasei Pharma Corporation	Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
CN101663262B (zh)	2006-12-01	2014-03-26	百时美施贵宝公司	用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2012037665A1 (en)	2010-09-24	2012-03-29	Oral Delivery Technology Ltd.	Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2986599A1 (en)	2013-04-17	2016-02-24	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
BR112021013807A2 (pt)	2019-01-18	2021-11-30	Astrazeneca Ab	Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3562257A (en) *	1967-10-28	1971-02-09	Tanabe Seiyaku Co	Benzothiazepine derivatives
BR6915295D0 (pt) *	1969-01-25	1973-04-12	Tanabe Seiyaku Co	Indicador cronologico de evento em transmissao televisada

1984
- 1984-05-16 US US06/610,856 patent/US4567175A/en not_active Expired - Lifetime
- 1984-05-29 CA CA000455370A patent/CA1237719A/en not_active Expired
- 1984-05-30 BG BG065689A patent/BG40964A3/xx unknown
- 1984-05-30 EP EP84106187A patent/EP0127882B1/en not_active Expired
- 1984-05-30 AT AT84106187T patent/ATE22889T1/de active
- 1984-05-30 DE DE8484106187T patent/DE3460972D1/de not_active Expired
- 1984-05-30 BG BG069785A patent/BG41130A3/xx unknown
- 1984-05-31 AU AU28873/84A patent/AU563093B2/en not_active Ceased
- 1984-05-31 PH PH30744A patent/PH21627A/en unknown
- 1984-05-31 ES ES533009A patent/ES8506677A1/es not_active Expired
- 1984-06-01 NO NO842203A patent/NO162518C/no unknown
- 1984-06-01 HU HU863905A patent/HU193865B/hu unknown
- 1984-06-01 DD DD84263713A patent/DD218619A5/de not_active IP Right Cessation
- 1984-06-01 DK DK272884A patent/DK167185B1/da active
- 1984-06-01 PT PT78682A patent/PT78682B/pt not_active IP Right Cessation
- 1984-06-01 HU HU842144A patent/HU191933B/hu not_active IP Right Cessation
- 1984-06-01 SU SU843749937A patent/SU1299508A3/ru active
- 1984-06-02 KR KR1019840003088A patent/KR900005697B1/ko not_active Expired
1985
- 1985-02-25 SU SU853856852A patent/SU1362401A3/ru active
- 1985-03-25 ES ES541557A patent/ES8602720A1/es not_active Expired
1986
- 1986-09-25 NO NO863823A patent/NO163566C/no unknown
- 1986-11-27 CA CA000524033A patent/CA1231097A/en not_active Expired
1987
- 1987-06-24 MY MYPI87000877A patent/MY101748A/en unknown
1988
- 1988-10-06 HK HK818/88A patent/HK81888A/en not_active IP Right Cessation
1992
- 1992-08-24 DK DK104792A patent/DK167186B1/da active

Also Published As

Publication number	Publication date
EP0127882B1 (en)	1986-10-15
AU563093B2 (en)	1987-06-25
NO162518B (no)	1989-10-02
CA1237719A (en)	1988-06-07
US4567175A (en)	1986-01-28
DK272884A (da)	1984-12-04
ES533009A0 (es)	1985-08-01
BG41130A3 (en)	1987-04-15
KR900005697B1 (ko)	1990-08-06
NO863823L (no)	1984-12-04
PT78682B (en)	1986-07-11
ES541557A0 (es)	1985-12-01
ES8506677A1 (es)	1985-08-01
DK167186B1 (da)	1993-09-13
NO842203L (no)	1984-12-04
DK167185B1 (da)	1993-09-13
PH21627A (en)	1987-12-11
DK104792D0 (da)	1992-08-24
DK104792A (da)	1992-08-24
PT78682A (pt)	1985-01-01
NO162518C (no)	1990-01-10
HU193865B (en)	1987-12-28
MY101748A (en)	1992-01-17
HUT37929A (en)	1986-03-28
EP0127882A1 (en)	1984-12-12
CA1231097A (en)	1988-01-05
NO863823D0 (no)	1986-09-25
BG40964A3 (en)	1987-03-14
ES8602720A1 (es)	1985-12-01
NO163566C (no)	1990-06-27
DK272884D0 (da)	1984-06-01
NO163566B (no)	1990-03-12
ATE22889T1 (de)	1986-11-15
KR850000033A (ko)	1985-02-25
AU2887384A (en)	1984-12-06
HU191933B (en)	1987-04-28
DE3460972D1 (en)	1986-11-20
SU1362401A3 (ru)	1987-12-23
SU1299508A3 (ru)	1987-03-23
HK81888A (en)	1988-10-14

Legal Events

Date	Code	Title	Description
1998-04-09	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DD218619A5 (de)	1985-02-13	Verfahren zur herstellung von neuen 8-chlor-1,5-benzothiazepin-derivaten
EP0154838B1 (en)	1988-07-06	Novel 1,5-benzothiazepine derivatives, processes for preparing the same and pharmaceutical compositions
SU1358784A3 (ru)	1987-12-07	Способ получени производных 1,5-бензтиазепина или их фармацевтически приемлемых кислотно-аддитивных солей
DD239202A5 (de)	1986-09-17	Verfahren zur herstellung von 9-chlor-1,5-benzothiazepin-derivaten
FR2468601A1 (fr)	1981-05-08	Nouveaux derives de flavanne utiles notamment comme anticonvulsivants
JPH0427213B2 (da)	1992-05-11
JPS59225174A (ja)	1984-12-18	ベンゾチアゼピン誘導体及びその製法
EP0019172A1 (de)	1980-11-26	6-Substituierte 11-Alkylen-morphantridine, Verfahren zu ihrer Herstellung und diese enthaltende therapeutische Mittel
DE69516257T2 (de)	2000-09-28	1,4-Benzoxazinderivate, es enthaltende pharmazeutische Zusammensetzung und seine Verwendung
DE3306146A1 (de)	1983-09-01	Pyridin-derivate und ihre verwendung als arzneimittel
AT401176B (de)	1996-07-25	Verfahren zur herstellung eines benzothiazepins
DE3884518T2 (de)	1994-03-24	Naphthothiazepin-Derivate und Verfahren zu ihrer Herstellung.
US4640930A (en)	1987-02-03	Naphtho(1,8-bc)-1,5-thiazocinones
US4278798A (en)	1981-07-14	1-Ethyl-1,4-dihydro-6-(2-naphthyl)-4-oxonicotinic acid and esters thereof
EP0124479B1 (de)	1988-01-20	Iminosulfonamide und Verfahren zu ihrer Herstellung, die pharmazeutische Präparate solche Verbindungen enthalten, sowie die Verbindungen zur Verwendung
AT394367B (de)	1992-03-25	Verfahren zur herstellung eines 1,5-benzothiazepinderivates oder eines salzes davon
EP0209022A1 (de)	1987-01-21	4-Substituierte 10-Cyanmethylen-thieno[4,3-e]-benzo-azepine
US4374261A (en)	1983-02-15	1-Ethyl-1,4-dihydro-6-(2-naphthyl)-4-oxo-nicotinic acid and esters thereof
GB2154578A (en)	1985-09-11	Novel 1,5-benzothiazepine derivatives and processes for preparing the same
AT395010B (de)	1992-08-25	Verfahren zur herstellung von 1,5-benzothiazepinderivaten und von deren salzen
FR2493314A1 (fr)	1982-05-07	Derives de 5-(o-aminoacyl)-3-carbalcoxyamino-10,11-dihydro-5h-dibenzo (b, f) azepine, leur procede de preparation et leur application therapeutique
JPS6313966B2 (da)	1988-03-29
JPH0376290B2 (da)	1991-12-05
CH618982A5 (en)	1980-08-29	Process for the preparation of new thiazolo[3,4-b]isoquinoline derivatives